#7597. Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo

October 2026publication date
Proposal available till 20-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Environmental Engineering;
Biomedical Engineering;
Molecular Biology;
Cell Biology;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2510 $1340 $1170 $1000 $
Contract №7597.1 Contract №7597.2 Contract №7597.3 Contract №7597.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

Abstract:
Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells. Herein, using an engineered hypoxia responding nirB promoter, we developed an engineered Escherichia coli BW25133 strain capable of expressing cardiac peptides and GFP signaling protein under hypoxic condition for spatiotemporal targeting of mice mammary tumors.
Keywords:
Angiogenesis; Cardiac peptides; CD31; Cytokines; MMP9; VEGFR2

Contacts :
0